MedTrace Logo

Resistance Training Adaptations and Caffeine Intake

NCT07410195 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-07-14

No results posted yet for this study

Summary

This parallel-group, randomized, double-blind, placebo-controlled trial investigates the effects of three different caffeine supplementation strategies on resistance training-induced adaptations in 120 caffeine-naive, inactive young adult males. Participants will undergo a 10-week supervised resistance training program. The four supplementation strategies are: (1) constant daily low-moderate dosing (4 mg/kg/day), (2) gradually escalating dose (2 to 6 mg/kg across weeks), (3) training-day-only caffeine (4 mg/kg/day), and (4) placebo. Primary outcomes include maximal strength, body composition (lean body mass and fat mass), skeletal muscle thickness, and training volume progression. Secondary outcomes include muscular endurance, jump height, flight-time-to-contraction-time (FT:CT) ratio, mechanistic/biological variables (epinephrine, norepinephrine, cortisol, testosterone, creatine kinase, IGF-1), rate of perceived exertion, sleep/recovery parameters, and adverse effects.

Conditions

  • Muscle Hypotrophy
  • Exercise Performance
  • Muscle Strength
  • Adaptation

Interventions

DIETARY_SUPPLEMENT

Caffeine (Constant Daily Dose)

Oral caffeine capsule at 4 mg/kg body weight, consumed daily approximately 60 minutes before training sessions (on training days) or at the same time of day (on rest days).

DIETARY_SUPPLEMENT

Caffeine (Escalating Dose)

• Oral caffeine starting at 2 mg/kg/day and increasing incrementally to reach 6 mg/kg/day by week 10.

DIETARY_SUPPLEMENT

Caffeine (Training Days Only)

Oral caffeine capsule at 4 mg/kg body weight, consumed only on training days approximately 60 minutes before exercise.

DIETARY_SUPPLEMENT

placebo capsule

Oral placebo capsule (250 mg cellulose), consumed daily approximately 60 minutes before training sessions (on training days) or at the same time of day (on rest days).

Sponsors & Collaborators

  • İstanbul Yeni Yüzyıl Üniversitesi

    collaborator OTHER

  • Istanbul University - Cerrahpasa

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-20
Primary Completion
2026-05-30
Completion
2026-06-07

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07410195 on ClinicalTrials.gov